The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients

Inclusion criteria * Meet criteria of enhanced recovery after surgery (ERAS); * Mechanical ventilated when enrolled and have estimation of more than 10 hours of mechanical ventilation in ICU * Aged between 18-75 years old AND 18kg/m2 ≤ BMI ≤ 30 kg/m2; * Clearly know the purpose and objective of this clinical study and voluntarily enrolled. Criteria of ERAS: (1) without dysfunction of nervous system or Glasgow Coma Score \> 12; (2) a satisfied glucose level (random blood glucose\<11.1mmol/L during screening stage) for diabetes mellitus patients; (3) Without acute coronary syndrome in recent 6 months; (4) Without bradycardia and third-degree atrioventricular block (except for patients with pacemaker) during screening stage; (5) systolic blood pressure\>90mmHg with no usage of vasoactive agent during screening stage; (6) without mental illness (schizophrenia, depressive disorder), cognitive dysfunction (identified by MMSE), epilepsy, history of abuse of psychotropic or anesthesia medication; (7) without disorder of coagulation function (PT/INR/APTT \> 1.5×upper limit), bleeding tendency (active peptic ulcer), under treatment of thrombolysis and anticoagulant; (8) without disorder of liver function (ALT/AST \> 2×upper limit and total bilirubin\>1.5×upper limit); (9) without disorder of renal function (Creatine or BUN/Urea\>1.5×upper limit); without dialysis patients. Exclusion criteria * Allergy to component of Remimazolam besylate for injection; * Woman in gestation and lactation period; * Enrolled in other clinical trails in recent 3 months; * Other circumstance that identified by researchers that do not suitable for this clinical trial.